Evidence map›Paper›PMID 40346726›Full record

ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2025

High rates of diagnostic discordance and co-pathology: Insights into PSP from the NACC dataset.

Tanav Popli, Subhamoy Pal, Allyson Gregoire, Jonathan M Reader, Alexis Passamani, Kelly M Bakulski, Arijit Bhaumik, Emile Pinarbasi, Henry Paulson, Amanda Cook Maher

Abstract read
In one paragraph

Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Comorbid pathologies and their impact on progressive supranuclear palsy: current view.Journal of neural transmission (Vienna, Austria : 1996) · 2026
    Review
  3. Article
  4. Review
  5. Article
  6. High rates of diagnostic discordance and co-pathology: Insights into PSP from the NACC dataset.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Tanav PopliMichigan Alzheimer's Disease Research Center, Ann Arbor, Michigan, USA.
Subhamoy PalMichigan Alzheimer's Disease Research Center, Ann Arbor, Michigan, USA.
Allyson GregoireMichigan Alzheimer's Disease Research Center, Ann Arbor, Michigan, USA.
Jonathan M ReaderMichigan Alzheimer's Disease Research Center, Ann Arbor, Michigan, USA.
Alexis PassamaniMichigan Alzheimer's Disease Research Center, Ann Arbor, Michigan, USA.
Kelly M BakulskiMichigan Alzheimer's Disease Research Center, Ann Arbor, Michigan, USA.
Arijit BhaumikMichigan Alzheimer's Disease Research Center, Ann Arbor, Michigan, USA.
Emile PinarbasiDepartment of Pathology, University of Michigan, Ann Arbor, Michigan, USA.
Henry PaulsonMichigan Alzheimer's Disease Research Center, Ann Arbor, Michigan, USA.
Amanda Cook MaherMichigan Alzheimer's Disease Research Center, Ann Arbor, Michigan, USA.

Funding

National Alzheimer's Coordinating CenterU24AG072122 · NIA · UNIVERSITY OF WASHINGTON · PI STEPHENS, KARI A · 2021 to 2025
$45.8M
Research Education ComponentP30AG062422 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Gil Dan Rabinovici · 2019 to 2026
$36.9M
Research Education ComponentP30AG062421 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI Teresa Gomez-Isla · 2019 to 2026
$36.5M
UCSD Shiley-Marcos Alzheimer's Disease Research Center P30P30AG062429 · NIA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Mark W Bondi · 2019 to 2026
$34.9M
Wisconsin Alzheimer's Disease Research CenterP30AG062715 · NIA · UNIVERSITY OF WISCONSIN-MADISON · PI Barbara Brigitta Bendlin · 2019 to 2026
$34.5M
Research Education ComponentP30AG062677 · NIA · MAYO CLINIC ROCHESTER · PI NILUFER ERTEKIN-TANER · 2019 to 2026
$33.5M
Research Education ComponentP30AG066514 · NIA · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Carolyn Wei Zhu · 2020 to 2026
$31.0M
Yale Alzheimer Disease Research CenterP30AG066508 · NIA · YALE UNIVERSITY · PI STEPHEN M STRITTMATTER, CHRISTOPHER H VAN DYCK · 2020 to 2026
$30.2M
Research Education CoreP30AG066462 · NIA · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Miguel Arce · 2020 to 2026
$30.1M
Research Education ComponentP30AG066468 · NIA · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI C. Elizabeth Shaaban · 2020 to 2026
$29.4M
Research Education ComponentP30AG066507 · NIA · JOHNS HOPKINS UNIVERSITY · PI MARILYN S. ALBERT · 2020 to 2026
$29.3M
University of Washington Alzheimer's Disease Research CenterP30AG066509 · NIA · UNIVERSITY OF WASHINGTON · PI Thomas J. Grabowski · 2020 to 2026
$29.0M
American Brain FoundationAssociation for Frontotemporal DegenerationNIA NIH HHS P20 AG068024NIA NIH HHS P20 AG068053NIA NIH HHS P20 AG068077NIA NIH HHS P20 AG068082NIA NIH HHS P30 AG062421NIA NIH HHS P30 AG062422NIA NIH HHS P30 AG062429NIA NIH HHS P30 AG062677NIA NIH HHS P30 AG062715NIA NIH HHS P30 AG066444NIA NIH HHS P30 AG066462NIA NIH HHS P30 AG066468NIA NIH HHS P30 AG066506NIA NIH HHS P30 AG066507NIA NIH HHS P30 AG066508NIA NIH HHS P30 AG066509NIA NIH HHS P30 AG066511NIA NIH HHS P30 AG066512NIA NIH HHS P30 AG066514NIA NIH HHS P30 AG066515NIA NIH HHS P30 AG066518NIA NIH HHS P30 AG066519NIA NIH HHS P30 AG066530NIA NIH HHS P30 AG066546NIA NIH HHS P30AG07293NIA NIH HHS P30 AG072931NIA NIH HHS P30 AG072946NIA NIH HHS P30 AG072947NIA NIH HHS P30 AG072958NIA NIH HHS P30 AG072959NIA NIH HHS P30 AG072972NIA NIH HHS P30 AG072973NIA NIH HHS P30 AG072975NIA NIH HHS P30 AG072976NIA NIH HHS P30 AG072977NIA NIH HHS P30 AG072978NIA NIH HHS P30 AG072979NIA NIH HHS P30 AG086401NIA NIH HHS P30 AG086404NIA NIH HHS R01 AG079280NIA NIH HHS T32 AG062403NIA NIH HHS T32-AG062403NIA NIH HHS U24 AG072122NINDS NIH HHS R35 NS122302NINDS NIH HHS R35-NS122302
6 · The paper itself

Abstract

introductionClinical features associated with accurate clinico-pathologic correlation within cognitive-predominant progressive supranuclear palsy (PSP) presentations have not been extensively studied. We identified features affecting PSP diagnosis within the National Alzheimer's Coordinating Center (NACC) dataset, a cognitive/behavioral research database.

methodsAutopsied NACC participants with clinical or neuropathologic PSP diagnoses were categorized by diagnostic modality (Clinical-only, Neuropathology-only, both). Group differences in clinical, demographic, neuropsychologic, and neuropathologic features were assessed.

resultsOnly 38.8% of neuropathologically identified PSP had clinical PSP diagnosis while 63.5% of clinically identified PSP had PSP pathology. Neuropathology-only cases had fewer motor symptoms and better processing speed/executive functioning than the Clinical-Neuropathology group. Nearly 70% demonstrated co-neuropathologies including Alzheimer-type, Lewy body, and corticobasal degeneration pathologies. DISCUSSION: Within NACC, discordant clinical and neuropathologic PSP diagnoses highlight the heterogeneity of PSP presentation, possibly driven by reliance on "classic" ante mortem symptoms. Further studies should assess the impact of co-pathology on clinical neurodegenerative disease presentations. HIGHLIGHTS: A high rate of clinico-pathologic PSP diagnostic discordance is seen within NACC. Cases without clinical PSP diagnosis had fewer classic motor and cognitive symptoms. Isolated PSP neuropathology is uncommon, with nearly 70% showing co-neuropathology.

Indexed as

BrainSupranuclear Palsy, ProgressiveAgedAged, 80 and overAlzheimer DiseaseAutopsyDatabases, FactualFemaleHumansMaleNeuropsychological TestsAlzheimer's disease research centerclinical‐pathologic correlationco‐neuropathologydisease heterogeneitynational Alzheimer's coordinating centerprogressive supranuclear palsy

Identifiers

PMID40346726
PMCPMC12064413

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.